Carlson Capital L P Lantern Pharma Inc. Transaction History

Carlson Capital L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$2.48 - $4.39 $86,800 - $153,650	-35,000 Reduced 36.84%	60,000 $256,000
Q2 2023 Aug 10, 2023	SELL	$4.56 - $6.02 $136,344 - $179,998	-29,900 Reduced 23.94%	95,000 $535,000
Q1 2023 May 12, 2023	SELL	$4.3 - $6.2 $56,330 - $81,220	-13,100 Reduced 9.49%	124,900 $603,000
Q4 2022 Feb 14, 2023	SELL	$4.19 - $6.04 $125,700 - $181,200	-30,000 Reduced 17.86%	138,000 $833,000
Q3 2022 Nov 14, 2022	SELL	$4.59 - $6.5 $9,180 - $13,000	-2,000 Reduced 1.18%	168,000 $803,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.45 $13,014 - $20,115	2,700 Added 1.61%	170,000 $971,000
Q1 2022 May 13, 2022	BUY	$5.6 - $8.22 $236,879 - $347,706	42,300 Added 33.84%	167,300 $1.2 Million
Q4 2021 Feb 11, 2022	BUY	$7.11 - $11.04 $888,750 - $1.38 Million	125,000 New	125,000 $998,000

1.31M

39.8K

6.1K

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $37M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

Get notified when there are updates to the investment portfolio of Carlson Capital L P, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital L P with notifications on news.